Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Another drug approval for Exelixis. Why Alnylam’s stock is under pressure today

January 15, 2019 0

More good news came from Exelixis (EXEL). It was expected by many but not by those who ignore the good news in favor of any negative news or lack of news. The announced news is that the FDA approved Exelixis’ Cabometyx® (cabozantinib) for hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib. More good news is Exelixis’ announcement that the firm is …

Why the new approval of Exelixis’ blood pressure drug Minnebro...

The importance of the FDA granting Fast Track Designation to...

Rhythm Pharmaceutical: Updates on trial results from genetic-derived obesity

Gilead: On the road towards realizing its goals. A new...

Agenus: Signing a lucrative and rewarding agreement with Gilead

AstraZeneca: Excellent collaborations. Moderna Therapeutics: Turning public. Will Prohost add...

A follow up on Gilead’s latest news

Exelixis initiates a phase 3 trial with cabozantinib combination for...

Celgene has important CAR T presentations at ASH

Vertex: Offering proof of leadership in treating Cystic Fibrosis

Loxo Oncology product Vitrakvi® has been granted FDA approval. The...

What the Aimmune and Nestlé Health Science agreement tells us

Jazz Pharmaceuticals has good, not bad news

RegenxBio: Another licensing agreement providing additional validation of its NAV...

About Illumina’s acquisition

Observing Array Biopharma

Alleviating osteoarthritis pain without the need for opioid drugs

Amgen’s product Amgevita, a biosimilar to adalimumab, will be launched...

$Exelixis initiates phase 3 trial with Cabometyx in radioiodine-refractory differentiated thyroid cancer (DTC) patients$

Exelixis initiates phase 3 trial with Cabometyx in radioiodine-refractory differentiated...

Today’s Highlights

Lipocine’s product, LPCN-1144, has promising results in decreasing the risk of NASH in non-alcoholic fatty liver disease

January 17, 2019 0

Lipocine (LPCN), a specialty pharmaceutical company, announced that an approximately eight-week top-line study using LPCN 1144 …

The FDA committee voted 19 to 1 in favor of approving Amgen’s & UCB’s new osteoporosis product Evenity

January 17, 2019 0

On January 8, 2019 the osteoporosis monoclonal antibody Evenity (romosozumab) developed by Amgen and UCB was …

Japan approved Gilead’s product Epclusa®. See Also: A collaboration agreement with Yuhan

January 8, 2019 0

Gilead Sciences (GILD) has news that begins with an announcement today that Japan’s Ministry of Health, Labour and …

Why Loxo Oncology’s and Sage Therapeutics’ stocks staged a Rally today

January 7, 2019 0

Why Loxo Oncology and Sage Therapeutics Have Occupied Today's Headline News LOXO Oncology Eli Lilly (LILY) announced …

Bristol-Myers to acquire Celgene. Was this move really a surprise?

January 3, 2019 0

Bristol-Myers Squibb (BMY) will acquire Celgene (CELG) in a cash and stock transaction with an equity value of …

Small firms developing improved CAR T immunotherapy products.

December 28, 2018 0

We have a few small clinical stage firms in the Prohost Portfolio that were established with the …

Prohost greetings and opinions

December 24, 2018 0

We Wish You A Happy Spiritual Season and A Happy New Year 2019. We Hope that …

Proteostasis: Its $100 million agreement with Genentech seems not enough to motivate investors to buy into the stock

December 18, 2018 0

Proteostasis (PTI) signed a worldwide, exclusive license agreement with Genentech about licensing rights to potential therapeutic small …

Great biotech news in a bizarre market. Incyte has two consecutive good news

December 17, 2018 0

During the departed week, outstanding advancements and improvements in various clinical disciplines filled the media. What’s …

Amgen, Rhythm Pharmaceuticals and an important story to know

December 12, 2018 0

Amgen Higher Dividends For those who invest in top-tier biotech firms for dividend payments, in addition …

The Week in Review

Politics and the Market

December 11, 2018 0

The Week in Review #35 Politics and the Market The market tumbled today as Theresa May, …

Improving on immunotherapy and preventing one of its serious side effects

November 13, 2018 0

The Week in Review #34 Improving on Immunotherapy and preventing one of its serious side effects. …

We call it the bad market

October 30, 2018 0

The Week in Review #33 WE CALL IT THE BAD MARKET The Federal Reserve’s raising of …

Positive News

October 22, 2018 0

The Week in Review #32 POSITIVE NEWS PROTEOSTASIS THERAPEUTICS Cystic Fibrosis Two days ago, a clinical-stage …

Outperformance, underperformance and volatility

October 2, 2018 0

The Week in Review #31 IN THE DEPARTED WEEK NOVEL MIGRAINE DRUGS ARE APPROVED ELI LILLY …

Three important news

September 25, 2018 0

The Week in Review #30 FROM THE DEPARTED WEEK In the past week, we came across …

What is looking good in the aggressive portfolio

September 10, 2018 0

The Week in Review #29 PROHOST AGGRESSIVE PORTFOLIO - The aggressive portfolio hosts biotech firms with …

Outperforming, favorite, and undervalued biotech firms

September 3, 2018 0

The Week in Review #28 The approval of revolutionary products created by biotech firms with solid …

Bombarding future treatment approaches

August 15, 2018 0

The Week in Review #27 PRIORITY TOPICS: CRISPR GENE EDITING, GENETIC ENGINEERING & ANTISENSE TECHNOLOGY The choice of these …

Stories about research, clinical trials results and an FDA ruling

July 9, 2018 0

The Week in Review #26 IN THE BIOTECH WORLD - RESEARCH - IMPROVING CRISPR GENE EDITING The problem …

Prohost Letters

End of the Year Decisions

January 15, 2019 0

Prohost Letter #426 End of the Year Decisions For 2019 We decided to make this Prohost …

The NEW Prohost Portfolio for 2019

January 3, 2019 0

The NEW Prohost Portfolio Small Important Changes We are making some very small but important changes …

When common sense fails to explain market performance

December 3, 2018 0

Prohost Letter #425 When Common Sense Fails to Explain the Market Performance It is not unusual …

Following the Stars. Less Science and More Logic

October 14, 2018 0

Prohost Letter #424 Following the Stars Less Science and More Logic We reiterate that while a …

Victims of fear and misunderstanding

August 1, 2018 0

ProhostLetter #423 TOMORROW’S THERAPEUTICS TODAY For a more or less fair evaluation of biotechnology and pharmaceutical …

New stock selection and re-evaluation

June 8, 2018 0

Prohost Letter #422 SUMMARY OF THE PAST ISSUE ARTICLE - REVISITING PROMISING FIRMS (PART1) - The …

Revisiting Biotech Companies We Highlighted

May 25, 2018 0

Prohost Letter #421 PRIVATE LESSONS - Stock prices of publicly-traded biotech companies oscillate for the same …

Real Breakthroughs

April 17, 2018 0

Prohost Letter #420 REAL BREAKTHROUGHS - One Has Already Been Used and the Other Has Extraordinary …

The Prohost Portfolio: Updating the Stock Targets

March 15, 2018 0

Prohost Letter #419 RE-EVALUATION ONLY - The Prohost Portfolio comprises biotechnology and biopharmaceutical companies, that we …

Observing Queer Stories

March 2, 2018 0

Prohost Letter #418 Observing Queer Stories PORTOLA - Portola (PTLA) has been granted approval of an …